Intrepid Potash (IPI) Grants CEO Temporary Medical Leave of Abscence

On April 16, 2024, the Board of Directors (the “Board”) of Intrepid Potash (NYSE: IPI) granted Robert P. Jornayvaz III, Executive Chairman of the Board and Chief Executive Officer of the Company, a temporary medical leave of absence, effective immediately, as he recovers from his previously announced accident. In connection with Mr. Jornayvaz’s medical leave, the Board temporarily delegated all responsibilities of the Chairman of the Board to Barth Whitham, Lead Director.

In addition, on the same date, the Board appointed Matthew D. Preston, the Company’s Chief Financial Officer, as acting principal executive officer of the Company. Mr. Preston will continue to serve as the Company’s Chief Financial Officer while he concurrently serves as principal financial officer and acting principal executive officer for SEC reporting purposes. In addition to his compensation for his role as Chief Financial Officer, Mr. Preston will receive additional cash compensation of $50,000 per month for so long as he is serving as acting principal executive officer.

The information with respect to Mr. Preston’s background as required by Items 401(b), (d), (e) and Item 404(a) of Regulation S-K is set forth in the Company’s Definitive Proxy Statement for its 2024 Annual Meeting of Stockholders, filed with the Securities and Exchange Commission on April 4, 2024, and is incorporated herein by reference.

On April 16, 2024, the Board, pursuant to the Restated Certificate of Incorporation of the Company and the Amended and Restated Bylaws of the Company, approved an increase of the size of the Board from six directors to seven directors, and, upon the recommendation of the Nominating and Corporate Governance Committee, appointed Hugh E. Harvey, Jr. to serve as a Class III director on the Board, with a term expiring at the 2026 Annual Meeting of Stockholders.

The Board also appointed Mr. Harvey to serve on each of the Board’s Audit Committee, Compensation Committee, Nominating and Corporate Governance Committee, Strategy Committee, and Environmental, Health, Safety, and Sustainability Committee, each effective immediately. As compensation for his service, Mr. Harvey will receive the Company’s standard compensation for non-employee directors, including an annual equity award, as presently described under “Non-Employee Director Compensation Policy” in the Company’s Definitive Proxy Statement for its 2024 Annual Meeting of Stockholders. There are no understandings or arrangements with any person pursuant to which Mr. Harvey was selected as a director, and Mr. Harvey is not party to any related party transaction required to be reported pursuant to Item 404(a) of Regulation S-K.

The Board considered the independence of Mr. Harvey under New York Stock Exchange (“NYSE”) listing standards and concluded that Mr. Harvey is an independent director under the applicable NYSE standards.

You May Also Be Interested In

• Change Agents forms counter-drone subsidiary, adds retired general
• HomeTrust Bancshares completes share buyback, approves new 5% program
• Prologis prices $2.1 billion common stock offering